In conclusion, this study provides compelling evidence that MYCN amplification extends beyond tumor growth to influence immune evasion pathways and glycosylation processes in neuroblastoma, potentially shaping the immune landscape in ways that limit immune engagement. The gene discussed is MYCN; the disease is neoplasm.